Comment Permalink

Thanks Ben :) Looking for a better study - here's a something with an imperfect but not too bad on the surface RCT protocol - which found pretty much no effect between full healthcare coverage and no healthcare coverage in the context of Ghana.

Such a shame these important questions are littered with such bad work.

Effect of Removing Direct Payment for Health Care on Utilisation and Health Outcomes in Ghanaian Children: A Randomised Controlled Trial

GabrielEhrnstGrundin10y1

There's nothing inherently wrong with observational studies. RCTs and observational studies may be on different rungs (or tiers) in the hierarchy of evidence, but that only means we have to put their conclusions into the proper context. This, of course, is not always easy for laymen like us.

Ben Kuhn

10y

The Ghana study didn't have enough statistical power to detect a change in all-cause mortality, even if the intervention caused ont. (Heck, it was barely powered to detect a change in anemia rates; they powered it to detect an absolute difference of 4% in anemia levels, but the anemia level was only 3% in the control group!) The authors don't even bother to give a confidence interval on the odds ratio for mortality that I can find, but you can extrapolate by taking the CI for anemia (0.66-1.67) and noting that mortality was even rarer than anemia in their sample. The observed hazard ratio in Burkina Faso (~0.5) is probably within the confidence interval of the Ghana study. And, even if this study had found a convincing demonstration of no effect, it wouldn't necessarily be inconsistent with the other study. Remember, they're different programs in different countries; it may be that health insurance works well in Burkina Faso but not in Ghana for some reason or other. I would be wary of calling either of the studies "bad work." The authors seem mostly aware of the relevant caveats (except perhaps the issue of power in the Ghana study); the problems is more that it's very easy to over-interpret or falsely generalize. Admittedly most development economics studies (and studies in general) could do better at conveying the limitations of their work, but it's not like there are glaring flaws in the studies themselves.

See in context

The problem with development research

by tomstocker

Apr 28 20151 min read 6

2

Frontpage

Recently I posted this:

This seems too good to be true.

I'd like people to confirm that my eyes aren't square:

A reduced risk of death from 21 in 1000 person years (assuming - this isn't explicit in the trial write up - person years corresponds to years under 5) to 11 deaths per 1000 person years for under 5s, who are covered by a micro-health insurance programme in rural Burkina Faso that costs around $1/year.

This translates to 1 infant death averted in every 100 infant years covered by the programme?

So 1 infant death per $120 assuming admin expenses of $20?

This seems unbelievable.

Unbelievable that there's a potential opportunity that effective.

Unbelievable that $1/yr can provide effective health coverage.

If it does hold for Burkina - the question is whether it will hold for other contexts?

You can read the original study here

http://www.globalhealthaction.net/index.php/gha/article/view/27327

there is disappointingly little raw data in it, but the researchers seem to be from a half reputable medical school in Germany.

Interested in people's thoughts - bunk?

Ben Kuhn's comment answers it pretty clearly. My eyes were square.

The trial I subsequently found to contradict this was much more persuasive - this doesn't look that promising but it might be depending on the context.

2 Reactions

Comments6

Sorted by

New & upvoted

Click to highlight new comments since: Today at 4:02 AM

Ben Kuhn10y5

This is an observational study, not a randomized trial. As such, there are likely to be uncontrolled confounders that bias the inferred effect high compared to the true effect.

Also, I was going to note that there's a lot of cross-country heterogeneity in these programs, but then I realized that the authors misread the Rwanda study they cite; they write that

one study from Rwanda showed a small reduction of 3􏰪-14% in the mortality of enrolled infants

but in fact it was a reduction of 3-14 percentage points, which is huge. Actually, it's so huge that I'm a little confused; baseline infant mortality was only 8.6 per cent before the health insurance program started! This makes the high end (14 percentage points, from their instrumental variables model) implausible as an estimate of the population effect, since that would require insurance-seeking to be highly correlated with infant mortality.

Anyway, that notwithstanding, I would still expect external validity to be limited, given that other studies have observed substantially different results.

tomstocker10y1

Such a shame these important questions are littered with such bad work.

Effect of Removing Direct Payment for Health Care on Utilisation and Health Outcomes in Ghanaian Children: A Randomised Controlled Trial

Ben Kuhn10y2

The authors don't even bother to give a confidence interval on the odds ratio for mortality that I can find, but you can extrapolate by taking the CI for anemia (0.66-1.67) and noting that mortality was even rarer than anemia in their sample. The observed hazard ratio in Burkina Faso (~0.5) is probably within the confidence interval of the Ghana study.

And, even if this study had found a convincing demonstration of no effect, it wouldn't necessarily be inconsistent with the other study. Remember, they're different programs in different countries; it may be that health insurance works well in Burkina Faso but not in Ghana for some reason or other.

I would be wary of calling either of the studies "bad work." The authors seem mostly aware of the relevant caveats (except perhaps the issue of power in the Ghana study); the problems is more that it's very easy to over-interpret or falsely generalize. Admittedly most development economics studies (and studies in general) could do better at conveying the limitations of their work, but it's not like there are glaring flaws in the studies themselves.

tomstocker10y0

OK, thanks for the analysis, I would have assumed that 1,000+ in each arm was enough to show something if something was there but guess I didn't take into account the rarity of childhood mortality. Soz.

Ben Kuhn10y2

Yup. The way in which sample size matters is that it decreases the size of the confidence intervals, but there are other things that affect that as well. So the best way to tell whether the sample size is large enough is looking at the confidence intervals directly.

GabrielEhrnstGrundin10y1